349 related articles for article (PubMed ID: 32749731)
1. Oral drug delivery with nanoparticles into the gastrointestinal mucosa.
Liu J; Leng P; Liu Y
Fundam Clin Pharmacol; 2021 Feb; 35(1):86-96. PubMed ID: 32749731
[TBL] [Abstract][Full Text] [Related]
2. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers.
Ensign LM; Cone R; Hanes J
Adv Drug Deliv Rev; 2012 May; 64(6):557-70. PubMed ID: 22212900
[TBL] [Abstract][Full Text] [Related]
3. The Influence of Nanoparticle Properties on Oral Bioavailability of Drugs.
Wang Y; Pi C; Feng X; Hou Y; Zhao L; Wei Y
Int J Nanomedicine; 2020; 15():6295-6310. PubMed ID: 32943863
[TBL] [Abstract][Full Text] [Related]
4. The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery.
Moss DM; Curley P; Kinvig H; Hoskins C; Owen A
Expert Rev Gastroenterol Hepatol; 2018 Mar; 12(3):223-236. PubMed ID: 29088978
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of Nanoparticle Transport across Intestinal Tissue: An Oral Delivery Perspective.
Ejazi SA; Louisthelmy R; Maisel K
ACS Nano; 2023 Jul; 17(14):13044-13061. PubMed ID: 37410891
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of mesoporous silica nanoparticles for oral drug delivery - current status and perspective of MSNs drug carriers.
Florek J; Caillard R; Kleitz F
Nanoscale; 2017 Oct; 9(40):15252-15277. PubMed ID: 28984885
[TBL] [Abstract][Full Text] [Related]
7. Enhanced oral absorption and anticancer efficacy of cabazitaxel by overcoming intestinal mucus and epithelium barriers using surface polyethylene oxide (PEO) decorated positively charged polymer-lipid hybrid nanoparticles.
Ren T; Wang Q; Xu Y; Cong L; Gou J; Tao X; Zhang Y; He H; Yin T; Zhang H; Zhang Y; Tang X
J Control Release; 2018 Jan; 269():423-438. PubMed ID: 29133120
[TBL] [Abstract][Full Text] [Related]
8. Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles.
Yuan H; Chen CY; Chai GH; Du YZ; Hu FQ
Mol Pharm; 2013 May; 10(5):1865-73. PubMed ID: 23495754
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the cytotoxicity, genotoxicity and mucus permeation capacity of several surface modified poly(anhydride) nanoparticles designed for oral drug delivery.
Iglesias T; López de Cerain A; Irache JM; Martín-Arbella N; Wilcox M; Pearson J; Azqueta A
Int J Pharm; 2017 Jan; 517(1-2):67-79. PubMed ID: 27908629
[TBL] [Abstract][Full Text] [Related]
10. Potential of Lipid Nanoparticles (SLNs and NLCs) in Enhancing Oral Bioavailability of Drugs with Poor Intestinal Permeability.
Talegaonkar S; Bhattacharyya A
AAPS PharmSciTech; 2019 Feb; 20(3):121. PubMed ID: 30805893
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery.
Yun Y; Cho YW; Park K
Adv Drug Deliv Rev; 2013 Jun; 65(6):822-32. PubMed ID: 23123292
[TBL] [Abstract][Full Text] [Related]
12. Oral absorption of peptides and nanoparticles across the human intestine: Opportunities, limitations and studies in human tissues.
Lundquist P; Artursson P
Adv Drug Deliv Rev; 2016 Nov; 106(Pt B):256-276. PubMed ID: 27496705
[TBL] [Abstract][Full Text] [Related]
13. Models and methods to evaluate transport of drug delivery systems across cellular barriers.
Ghaffarian R; Muro S
J Vis Exp; 2013 Oct; (80):e50638. PubMed ID: 24192611
[TBL] [Abstract][Full Text] [Related]
14. Challenges in Oral Drug Delivery and Applications of Lipid Nanoparticles as Potent Oral Drug Carriers for Managing Cardiovascular Risk Factors.
Okur NÜ; Siafaka PI; Gökçe EH
Curr Pharm Biotechnol; 2021; 22(7):892-905. PubMed ID: 32753006
[TBL] [Abstract][Full Text] [Related]
15. Enhancing insulin oral absorption by using mucoadhesive nanoparticles loaded with LMWP-linked insulin conjugates.
Sheng J; He H; Han L; Qin J; Chen S; Ru G; Li R; Yang P; Wang J; Yang VC
J Control Release; 2016 Jul; 233():181-90. PubMed ID: 27178809
[TBL] [Abstract][Full Text] [Related]
16. Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery.
Fan W; Xia D; Zhu Q; Li X; He S; Zhu C; Guo S; Hovgaard L; Yang M; Gan Y
Biomaterials; 2018 Jan; 151():13-23. PubMed ID: 29055774
[TBL] [Abstract][Full Text] [Related]
17. Engineering strategies to enhance nanoparticle-mediated oral delivery.
Yamanaka YJ; Leong KW
J Biomater Sci Polym Ed; 2008; 19(12):1549-70. PubMed ID: 19017470
[TBL] [Abstract][Full Text] [Related]
18. Self-emulsifying drug delivery systems in oral (poly)peptide drug delivery.
Leonaviciute G; Bernkop-Schnürch A
Expert Opin Drug Deliv; 2015; 12(11):1703-16. PubMed ID: 26477549
[TBL] [Abstract][Full Text] [Related]
19. Multifunctional matrices for oral peptide delivery.
Bernkop-Schnürch A; Walker G
Crit Rev Ther Drug Carrier Syst; 2001; 18(5):459-501. PubMed ID: 11763498
[TBL] [Abstract][Full Text] [Related]
20. Mucus as a barrier to drug delivery – understanding and mimicking the barrier properties.
Boegh M; Nielsen HM
Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):179-86. PubMed ID: 25349046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
